Intercept Pharma (ICPT) Receives a Hold from Stifel Nicolaus


Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Intercept Pharma (ICPT) today and set a price target of $29.00. The company’s shares closed last Thursday at $26.58, close to its 52-week low of $23.78.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 12.2% and a 50.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Phasebio Pharmaceuticals, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intercept Pharma with a $53.75 average price target, representing an 86.5% upside. In a report released yesterday, RBC Capital also reiterated a Hold rating on the stock with a $33.00 price target.

See today’s analyst top recommended stocks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $79.52 million and GAAP net loss of $66.47 million. In comparison, last year the company earned revenue of $61.95 million and had a GAAP net loss of $84.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts